We are excited to be sponsoring, speaking and exhibiting at the Advanced Therapies Integrates North, in Edinburgh, in April 2026.
Advanced Therapies Integrates North is dedicated to uniting industry leaders to drive and realize the full potential of Advanced Therapies and Medicinal Products (ATMPs). The event will focus on the key innovations within complex therapeutics, cell and gene therapies, regenerative medicines and tissue therapies and identify the challenges facing the industry, such as regulatory and commercial barriers to deploying transformational changes.
Hear live from Cell and Gene Therapy Catapult
Title: Opening Remarks
Speaker: Jacqueline Barry, Chief Clinical Officer, Cell and Gene Therapy Catapult
Time: 09:45 - 09:55
Title:Fireside Chat - Advanced Therapies: Patient to Population Impact
Explore how advanced therapies are transforming lives, reducing healthcare costs, and boosting economies through job creation and innovation. We’ll also touch on delivery challenges, from manufacturing to regulation.
Speaker: Jacqueline Barry, Chief Clinical Officer, Cell and Gene Therapy Catapult
Time: 10:00 - 10:20
Title:Digitally Driven
Digital technologies are reshaping the ATMP R&D landscape, driving faster, smarter and more efficient development pathways. This session will explore how emerging innovations are being harnessed in the UK to overcome process development, QC and manufacturing bottlenecks.
Panellist: Kevin Vela, Sr Collaboration Manager, Cell and Gene Therapy Catapult
Time: 10:25 - 11:05
Title:Trial Blazers
The UK boasts world-class clinical development infrastructure, but is it keeping pace with global competition in ATMPs? With insights from leading UK CROs and a review of the NIHR Advanced Therapy Treatment Centre (ATTC) funding one year on, we’ll explore key learnings and outline what’s next for advancing ATMP clinical development in the UK.
Facilitator: Emily Merrell, Director of ATTC Network Coordination, Cell and Gene Therapy Catapult
Time: 11:35 - 12:15
Title:The Price is Right?
How can we balance commercial viability of ATMPs with patient accessibility and affordability? This panel will examine the UK’s ATMP funding and reimbursement structure, exploring VPAG, funding hurdles, and how the UK can remain competitive on a global scale.
Panellist: Panos Kefalas, Director of Access Strategy, Cell and Gene Therapy Catapult
Time: 11:35 - 12:15